Lupin receives final USFDA approval for Atopic Dermatitis Lotion

Pharma major Lupin received the final approval from the United States Food and Drug Administration (FDA) for its Hydrocortisone Butyrate Lotion, 0.1%.

Hydrocortisone Butyrate Lotion, 0.1% is a generic version of PreCision Dermatology Incorporated's (PreCision) Locoid Lotion, 0.1%. The said lotion will be effective in the topical treatment of mild to moderate atopic dermatitis in patients of 3 months of age or older. Hydrocortisone Butyrate Lotion, had annual sales of approximately US$ 13.8 million in the US market, according to IQVIA MAT April 2018 data.

On Tuesday, shares of Lupin closed by over 2 per cent at Rs. 889.20 per share, up by 19.40 points. The share opened at Rs. 868.05 per share on the BSE. It reached its intraday high at Rs. 892 and intraday low was at Rs. 865.50 per share on the BSE. Meanwhile, the benchmark indices BSE Sensex closed at 38,285.75, up by 0.01 per cent and Nifty50 closed at 11,570.90, up by 0.17 per cent.